Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeoGenomics's change in inventory for the quarter that ended in Jun. 2026 was MXN47 Mil. It means NeoGenomics's inventory
declined by MXN47 Mil
from Mar. 2026 to Jun. 2026 .
NeoGenomics's change in inventory for the fiscal year that ended in Dec. 2025 was MXN-28 Mil. It means NeoGenomics's inventory
increased by MXN28 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
NeoGenomics's Days Inventory for the quarter that ended in Jun. 2026 was 24.09.
Inventory Turnover measures how fast the company turns over its inventory within a year.
NeoGenomics's Inventory Turnover for the quarter that ended in Jun. 2026 was 3.79.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NeoGenomics's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.14.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NeoGenomics's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeoGenomics Change In Inventory Related Terms
NeoGenomics Change In Inventory Historical Data
* Premium members only.
The historical data trend for NeoGenomics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN127 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of MXN127 Mil mean?
NeoGenomics (MEX:NEO) has a Change In Inventory of MXN127 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for NeoGenomics and its competitors.
Is NeoGenomics' Change In Inventory too high?
NeoGenomics' current Change In Inventory is MXN127 Mil. Overall, NeoGenomics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Change In Inventory compare to WGS and CDNA?
NeoGenomics' Change In Inventory of MXN127 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Medical Diagnostics & Research company?
A good Change In Inventory depends on the Medical Diagnostics & Research industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for NeoGenomics and its competitors. NeoGenomics's current Change In Inventory is MXN127 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
NeoGenomics (MEX:NEO) has a current Change In Inventory of MXN127 Mil. The stock's GF Value™ is MXN166.74, compared to a current price of MXN176.40 — trading 5.8% above its estimated fair value. The current Change In Inventory is MXN127 Mil. NeoGenomics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For NeoGenomics (MEX:NEO), the current Change In Inventory is MXN127 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeoGenomics (MEX:NEO) Overvalued in 2026?
Based on GuruFocus' analysis, NeoGenomics stock appears to be overvalued.
The current stock price of MXN176.40 is trading 5.8% above its estimated GF Value™ of MXN166.74.
Key valuation signals for MEX:NEO:
Change In Inventory: MXN127 Mil
GF Value™: MXN166.74 vs. price of MXN176.40 (5.8% above fair value)
No single metric tells the full story. See the MEX:NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
73GF Score
Get the complete analysis for MEX:NEO
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NEO has been successfully added to your 
